{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daunorubicin+Hydrochloride", "query": { "intervention": "Daunorubicin Hydrochloride" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1294, "total_pages": 130, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daunorubicin+Hydrochloride&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T21:28:26.345Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01387932", "title": "HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "HepaSphere/QuadraSphere Microspheres", "type": "DEVICE" }, { "name": "PVA, lipiodol, doxorubicin", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Merit Medical Systems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2011-06", "completion_date": "2021-02", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387932" }, { "nct_id": "NCT00290433", "title": "Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2003-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2020-09-23", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290433" }, { "nct_id": "NCT00068393", "title": "Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Renal Cell Carcinoma With Sarcomatoid Features" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "G-CSF (granulocyte-colony stimulating factor)", "type": "DRUG" }, { "name": "Neulasta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2004-02-24", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 92, "location_summary": "Los Angeles, California • Aurora, Colorado • Aurora, Illinois + 56 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068393" }, { "nct_id": "NCT00000626", "title": "Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hodgkin's Disease" ], "interventions": [ { "name": "Vinblastine sulfate", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 27, "start_date": null, "completion_date": "1999-02", "has_results": false, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000626" }, { "nct_id": "NCT05656248", "title": "Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloid Neoplasm" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" }, { "name": "MHA", "type": "DRUG" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 25, "start_date": "2023-01-17", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05656248" }, { "nct_id": "NCT03984448", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Double-Expressor Lymphoma", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 363, "start_date": "2019-10-22", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 634, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984448" }, { "nct_id": "NCT00206518", "title": "Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Taxotere/Docetaxel", "type": "DRUG" }, { "name": "Adriamycin/Cytoxan", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mothaffar Rimawi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 167, "start_date": "2004-09", "completion_date": "2016-10-10", "has_results": true, "last_update_posted_date": "2020-07-28", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00206518" }, { "nct_id": "NCT01760226", "title": "Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Post Transplant Lymphoproliferative Disorder", "Primary Mediastinal (Thymic) Large B-cell Lymphoma" ], "interventions": [ { "name": "DA-EPOCH-R for DLBCL, PTLD, AND PMBCL", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 4, "start_date": "2013-01", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01760226" }, { "nct_id": "NCT00136084", "title": "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myelocytic, Acute" ], "interventions": [ { "name": "Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone", "type": "DRUG" }, { "name": "Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 238, "start_date": "2002-08", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2012-12-05", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 8, "location_summary": "Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00136084" }, { "nct_id": "NCT00501826", "title": "Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Acute Lymphoblastic Leukemia", "T Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 160, "start_date": "2007-07-11", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-26T21:28:26.345Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00501826" } ] }